Genenta Science announces amendment to pact with AGC Biologics

Genenta Science (GNTA) announced that it has strengthened its partnership with contract development and manufacturing organization AGC Biologics by amending their Development and Master Services Agreement. “This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta’s cell therapy product, ensuring compliance with cGMP standards. This strategic move enhances Genenta’s production capabilities, potentially improving efficiency and reliability in its manufacturing processes. The newly approved methastatic Renal Cell Cancer Phase 1/2a trial began in Q4 2024, and Genenta expects to treat six patients by the end of the first half of 2025, while continuing progress with the Glioblastoma Multimforme study. In total, Genenta projects manufacturing 27 autologous drug products in 2025,” Genenta stated. “Our strengthened partnership with AGC Biologics represents our unwavering commitment to patients participating in our GBM and mRCC trials. This enhanced capacity ensures that we can treat a larger number of patients and further validate our therapeutic approach, bringing us closer to our vision of transforming cancer treatment through cell-based therapies,” said Pierluigi Paracchi, CEO and Co-founder of Genenta.